UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally
with the goals to expedite infusion to wider patient inclusion that includes those who were
previously excluded, such as pediatric patients with B-cell NHL and patients in primary
relapse.